29 August 2017
Visiongain’s new 147 page report Global Influenza Vaccines - World Industry Market Outlook 2017-2027; Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other indicates that the influenza vaccines market will generate revenues of $4.97bn in 2017.
The study analyses events, prospects and sales opportunities shaping the development, production and marketing of influenza vaccines. That investigation shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of companies providing these vaccines, assessing their potentials from 2016 onwards. This vaccines market holds many commercial opportunities from 2016, including rising sales in developed and emerging countries.
Visiongain predicts that the influenza vaccines market will continue to grow at a steady pace through 2017 – 2027. This growth is mainly driven by the ageing population globally and the increasing prevalence of chronic illness. Adding to this will be the growing demand from emerging markets as their economies prosper, their healthcare expenditures also rise.
The study shows how the market share for the various countries change due to political and economic structural changes, and also the emergence of new industry players. Further, the shifts in market share of the submarkets are also shown, shedding light on the future developments in the influenza vaccine technology. The study also includes the next major breakthrough that will transform the industry; the much awaited Universal Flu vaccine, which will provide immunity against all types of influenza viruses. A company that is currently developing this vaccine has also been interviewed in the report.
The pharmaceutical industry analyst at visiongain for this report said: “Prevalence of influenza rises globally. The most effective way to combat that widespread infection is through vaccination. As the world moves towards an ageing population, people’s susceptibility to influenza increases, raising demand for flu vaccines. Also improving healthcare systems, growing flu awareness and high birth rates in developing countries will fuel demand for existing and new influenza vaccines from 2017. The influenza vaccination industry thus holds great potential for progress and high sales. Vaccination is a stressful event, especially for children, and the company that can provide a uniquely non-stress vaccination will reap high rewards.
The influenza virus changes each year and new vaccines are required to maintain immunization against the infection. With this in mind, the influenza vaccine market can be assured of high demand. And the development of a universal influenza vaccine that provides protection against seasonal and pandemic strains of the virus could potentially transform the industry.”
Global Influenza Vaccines - World Industry Market Outlook 2017-2027; Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research (CROs), manufacturing (CMOs) and selling (CSOs).
Notes for Editors
If you are interested in a more detailed overview of this yearbook, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the energy, telecoms, pharmaceutical, defence and materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.
26 February 2021
The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.
22 February 2021
The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.
22 February 2021
The global behavioural Health market has been growing considerably owing to the rising pressure/stress at work, growing incidence and prevalence rate of depression and PTSD (Post Traumatic Stress Disorder) around the globe.